Adam Smith Conferences
Ministry of Healthcare of the Republic of Kazakhstan
Eurasian Economic Commission
SK-Pharmacy
Association of International Pharmaceutical Manufacturers in the Republic of Kazakhstan
Association for the Support and Development of Pharmaceutical Activities of the Republic of Kazakhstan
Forum Agenda
Pre-Forum Day, 3 March 2025
19:00
19:00
Welcome Reception and Networking Opportunities
-
Restaurant Gaia, Almaty
For the Forum participants, a transfer from the Swissotel Alatau to the venue and back will be organized.
08:00 – 09:00
08:00 – 09:00
Registration of participants, morning coffee, meeting with colleagues.
09:00 – 09:10
09:00 – 09:10
Start of the conference. Welcome speech of organizers
09:00 – 09:10
09:00 – 09:10
Начало конференции.
Приветственное слово организаторов
Приветственное слово организаторов
09:10 – 10:30
09:10 – 10:30
PLENARY DISCUSSION OF THE CAPTAINS OF THE PHARMACEUTICAL MARKET: The Future of Pharmaceuticals in the EAEU Countries — Strategic Challenges and Global Trends
- Impact of geopolitical changes on the manufacturing and supply of medicines
- Investments in the pharmaceutical sectors of the EAEU countries, strategies of global and local players
- Role of Big Pharma and government collaboration in improving access to new drugs
- Impact of digital development on the healthcare system
-
Moderator:
VYACHESLAV LOKSHINpresident of the Association of International Pharmaceutical Manufacturers
Impact of geopolitical changes on the manufacturing and supply of medicines -
YERZHAN NURLYBAYEV
Vice-Minister of Health of the Republic of Kazakhstan -
ERKEN ZHAKATAY
Chairman of the Board of SK-Pharmacy -
GULNARA KULKAYEVA
Chairman of the Board of the National Scientific Center for Health Development named after Salidat Kairbekova -
DMITRY KOZENKOV
Head of Pfizer Representative Office in Kazakhstan -
LARISA MATVEEVA
Executive Director, Association of International Pharmaceutical Manufacturers in the Russian Federation -
ADILET NAZARBAYEV
General Director «Johnson & Johnson Kazakhstan» -
TOYLAN ŞENEL
Head of F.Hoffmann-La Roche, Central Asia (Kazakhstan, Uzbekistan, Kyrgyzstan, Tajikistan, Mongolia) -
MARIA SHIPULEVA
General Manager, AstraZeneca Kazakhstan
10:30 – 10:50
10:30 – 10:50
Coffee break and business communication
10:50 – 12:30
10:50 – 12:30
PLENARY SESSION: Unified Registration of Medicines in the EAEU Countries and Uzbekistan. Cooperation without Borders!
Relevance: With the introduction of a unified system for registration of medicines in the EAEU countries, companies face new requirements and procedures that may affect the timing of drug entry into the market and overall availability. Discussion of this topic will be relevant in light of the integration of countries and the desire to simplify access to medicines for the population.
- How can unified registration speed up the process of bringing new drugs to markets?
- Advantages and disadvantages of a unified system for manufacturers and distributors.
- Expectations and reality: how do companies adapt to new requirements?
- What steps can be taken to optimize the registration process?
- What are the main challenges companies face in the unified registration process?
- Strategy for the Development of Pharmacopoeial Standards of the Eurasian Economic Union
- Expansion of Pharmaceutical Registration in the EAEU. Solutions and Realities.
-
Moderators:
VYACHESLAV LOKSHINPresident of the Association of International Pharmaceutical Manufacturers -
Moderators:
ELENA POPOVASenior Director, Association of International Pharmaceutical Manufacturers in the Russian Federation -
TALGAT MOMYSHEV
Director of the Technical Regulation and Accreditation Department, EEC -
ARDAK TULEGENOVA
Head of the Department for the Improvement of the State Pharmacopoeia of the Republic of Kazakhstan and the EAEU -
ALEVTINA SIMONOVA
Deputy Head of the Department for Management and Control of Evaluation, Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation -
TATEVIK YERITSYAN
Coordinator for Pharmaceutical and Medical Device Affairs within the EAEU at the State Non-Commercial Organization "Center for Expertise of Medicines and Medical Technologies," Ministry of Health of the Republic of Armenia (online) -
MANSHUK KURMANBAY
Head of the Department of Analysis and Monitoring of Pharmaceutical Activities of the Committee for Medical and Pharmaceutical Control of the Ministry of Healthcare of the Republic of Kazakhstan -
VADIM KALINICHENKO
Ministry of Health of the Russian Federation, Department of regulation or circulation of medicines and medical devices -
ALISHER TEMIROV
Director of the State Institution 'Center for Pharmaceutical Product Safety' of the Ministry of Health of the Republic of Uzbekistan (online) -
DMITRY ROZHDESTVENSKY
Head of the Department for Coordination of Pharmaceutical and Medical Device Affairs at the Technical Regulation and Accreditation Department of the EEC -
EKATERINA YAKOVLEVA
Director of Registration, AstraZeneca -
ROMAN DRAY
Director of the Research and Development Department of GEROPHARM
12:30 – 12:45
12:30 – 12:45
Technical break
12:45 – 14:05
12:45 – 14:05
PANEL DISCUSSION: Pricing in the Countries of the Eurasian Region. Challenges and Solutions for 2024-2025
- Approaches to price regulation of drug provision within the framework of public procurement programs in the countries of the Eurasian region and CIS countries. Impact on the availability of medicines
- Provision of medicines for the treatment of orphan diseases within the framework of the Eurasian Union and the experience of other countries
- Reference pricing mechanisms
- How price regulation works – the experience of other countries and regions
- Deregulation of retail prices for medicines in the commercial segment in the Republic of Kazakhstan
- Harmonization of Price Regulation in EAEU Countries
-
Moderator:
MARINA DURMANOVAPresident of the Association for the Support and Development of Pharmaceutical Activities of the Republic of Kazakhstan -
LYAZZAT AITYMBETOVA
Head of the Department of Preventive Control of the Committee for Medical and Pharmaceutical Control of the Ministry of Healthcare of the Republic of Kazakhstan -
ASEL ZHANATBEKOVA
Head of Department of price expertise for medicines,National Centre for Medicines and Medical Devices Expertise -
VITALY OMELYANOVSKY
General Director of FGBU "Center for Expertise and Quality Control of Medical Care" of the Ministry of Health of the Russian Federation (online) -
MIRA TUYAKBAEVA
Director of the Social Sector Department, Agency for the Protection and Development of Competition of the Republic of Kazakhstan -
ANATOLY YURASTOV
Head of the Social Sector and Services Department, Ministry of Antimonopoly Regulation and Trade of the Republic of Belarus (online) -
AMIR SULTANOV
Head of Pricing Committee, Association of Representative Offices of Foreign Pharmaceutical Companies in the Republic of Uzbekistan -
ASEL TURDALIEVA
Chief Specialist, Department of Medical Services Quality and Pharmaceutical Policy, Ministry of Health of the Kyrgyz Republic -
ZAFAR VAKHIDOV
Chairman of the Expert Council, Partner of the law firm, Vakhidov Partners -
YEVGENY ZEMLYANKIN
CEO, Amity International -
ANDREY IVANOV
Head of the Market Access Department, AstraZeneca -
ALEXANDER MARTYNENKO
Association of International Pharmaceutical Manufacturers of the Russian Federation (online)
14:05 – 14:20
14:05 – 14:20
FOCUS REPORT : Value Over Cost via Willingness-to- Pay Threshold (WTP) in Healthcare
-
ALIMA ALMADIYEVA
MD MSc, Advisor, Health Economics & Outcomes Research (HEOR) with the support of Novartis
14:20 – 15:00
14:20 – 15:00
Lunch
15:00 – 16:30
15:00 – 16:30
PANEL SESSION: Innovation and Patent Disputes: Balancing Intellectual Property Protection and Access to Medicines. The Factor of the High Level of Development of the Healthcare System
How to support the development of new, life-saving medicines while ensuring their availability to patients? Patents play a critical role in protecting the intellectual property of pharmaceutical companies by creating incentives for expensive and time-consuming research and development (R&D). But once a patent expires, the question of availability arises — how to ensure that needed drugs do not remain expensive and unavailable to most patients? Indeed, against the backdrop of challenges associated with the need for affordable innovative solutions, pressure on pharmaceutical companies from governments, regulators and society is increasing.
- How to ensure a balance incentives for innovation, access to medicines for patients and contribution to economic development?
- Current challenges and trends in the protection of intellectual property rights for pharmaceutical developments.
- What initiatives are aimed at harmonizing standards and strengthening the protection of intellectual property rights at the level of the EAEU countries?
- Protection of Data from Preclinical and Clinical Trials in the Registration of Medicinal Products
-
Moderator:
VADIM KUKAVAExecutive Director of the Association, Infarma -
AURELIA CHEBAN
Deputy Head of the Expertise Department, Head of the Chemistry and Medicine Department of the Eurasian Patent Office (EAPO) -
SHYNAR BAYDULLAYEVA
Head of the Department of Expertise of Medicines, National Centre for Medicines and Medical Devices Expertise -
MARINA SIROTINA
Deputy Chairman, Committee of Intellectual Property Rights of the Ministry of Justice of the Republic of Kazakhstan -
DARIA FEDOROVA
Deputy Director of the Medical Technology Transfer Centre, Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (online) -
SERGEY KLIMENKO
Партнер, РуководиPartner, Head of Nextons practiceтель практики Nextons -
ALEXANDER BYKOV
Director of Healthcare at R-Pharm -
OLGA BERYBAYEVA
Director of Legal Affairs, AstraZeneca -
LILIA DANILOVA
Legal Director for Pfizer in the Middle East and Africa, Saudi Arabia, Turkey, Central Asia and the Caucasus, Russia and Belarus -
SHAHRUKH USMANOV
Partner, GRATA -
MIKHAIL TSYFEROV
President of Petrovax Pharm
16:30 – 17:00
16:30 – 17:00
Coffee break and business communication
17:00 – 18:00
17:00 – 18:00
DISCUSSION: DIGITALIZATION OF THE HEALTHCARE SYSTEM
- Telemedicine, medical decision support system, electronic patient registers: current status and prospects
- How can pharmaceutical companies participate in the implementation of digital healthcare development programs?
- Global trends in the development of AI in healthcare and pharma
- Formation of a Unified Digital Space in Healthcare and the Common Data Market
- Information systems as a single digital space in diagnostic programs and clinical registers. Practical examples
-
Moderator:
ANDREY IVANOVHead of the Market Access Department, AstraZeneca -
AINA AZHIBAYEVA
Director of Corporate and Retail Solutions Department, Kazakhtelecom -
ANDRII BAHRIENKO
CEO, Edenlab -
NATALIA MUEVA
Head of Medical Programs, Аston Health -
SERGEY LYSENKO
Head of IT Innovations, Inkar -
VASILIY SVETLOV
Head of the Healthcare Digitalization Working Group at the AIPM of the Russian Federation (online)
18:00 – 20:00
18:00 – 20:00
End of Day One
Evening Reception & Informal Networking
Evening Reception & Informal Networking
08:30 – 09:00
08:30 – 09:00
Morning coffee and networking
09:00 – 10:00
09:00 – 10:00
PLENARY SESSION: Drug Labeling Systems. Challenges and Opportunities
- Impact of labeling systems on transparency and safety of medicines
- Impact on the work of wholesale companies and pharmacy organizations
- How can labeling help in the fight against counterfeit drugs? Are there other regulatory tools?
- Transition to new standards: challenges and solutions for the entire supply chain
- What are the main benefits of labelling systems for end consumers?
- Labeling of unregistered medicines in the Republic of Kazakhstan
-
Moderator:
MARINA DURMANOVAPresident of the Association for the Support and Development of Pharmaceutical Activities of the Republic of Kazakhstan -
LYAZZAT AITYMBETOVA
Head of the Department of Preventive Control of the Committee for Medical and Pharmaceutical Control of the Ministry of Healthcare of the Republic of Kazakhstan -
ERIK KULSHANOV
Chief of the Medical Equipment Department, SK-Pharmacy -
BIKESH KURMANGALIYEVA
CEO, Digital Economy Development Centre -
ALEKSANDRA TIKHONOVA
Project Manager (Pharmaceuticals), Department for Socially Significant Goods, Center for the Development of Advanced Technologies -
ALIYA ZHUMEKENOVA
Partner, Pharmaceuticals & Healthcare GRATA
10:10 – 11:30
10:10 – 11:30
EXPERT ANALYTICAL PANEL: Overview of Pharmaceutical Markets of the EAEU Countries, Results of 2024 and Forecasts for 2025
- Key figures and trends: Presentation of the latest data from analytical agencies on the dynamics of market growth and sales volume in the pharmaceutical industry in the EAEU countries. Discussion of key indicators for recent years and forecasts for 2024-2025.
- How is the demand for different categories of drugs changing (innovative drugs, generics, over-the-counter drugs, biosimilars)? Which segments are showing the most active growth?
- How do the markets of Russia, Kazakhstan, Uzbekistan, Belarus, Armenia and Kyrgyzstan differ in terms of volumes and growth rates? Influence of economic and regulatory factors on the development of pharmaceutical markets in each country.
- Impact of consumer behavior on the drug market: How are patient needs and preferences changing in the EAEU? For example, is there a growing demand for natural products, online consultations and purchasing drugs through electronic platforms?
- Risks and Opportunities for Business in the EAEU
-
Moderator:
ALEXANDER IVANOVHead of Strategic Consulting, Aston Health -
ADEL KALIEV
independent expert, ex-Deputy Director of the Antimonopoly Regulation Department of the EEC -
GULNARA KULKAEVA
Chairperson of the Board, RGP at PHW "National Scientific Center for Healthcare Development named after Salidat Kairbekova" -
EKATERINA MARKOVA
Director of Proxima Research Kazakhstan -
ZHIBEK KERIMBAEVA
COUNTRY HEAD KAZAKHSTAN &CIS, IQVIA
11:30 – 12:00
11:30 – 12:00
Coffee break
12:00 – 13:30
12:00 – 13:30
Parallel Sessions
Hall 1
Collaboration between local and international players. Strategic partnerships to expand distribution and adapt products to regional markets
- How can international companies use partnerships with local players to quickly launch new products in the EAEU countries?
- Adaptation of product portfolios and marketing strategies for local markets: localization of packaging and advertising campaigns, how to take into account regional needs and patient preferences and comply with national norms and standards?
- What legal and operational risks may arise in the process of international cooperation, and how to ensure compliance standards?
Moderator:
ZAFAR VAKHIDOV, Chairman of the Expert Council, Partner at the law firm "Vakhidov Partner
ZOKHID ERMATOV, Executive Director of the State Health Insurance Fund of the Republic of Uzbekistan
BOTAGOZ BEGIMBETOVA, Chief Operating officer,
VIVA Pharm LLP
LARISSA YEMELYANOVA, Partner, AEQUITAS law firm
DMITRY KOZENKOV, Head of Pfizer Representative Office in Kazakhstan
ANDREY KONOVALOV, General Director of Teva Kazakhstan"
ZAFAR VAKHIDOV, Chairman of the Expert Council, Partner at the law firm "Vakhidov Partner
ZOKHID ERMATOV, Executive Director of the State Health Insurance Fund of the Republic of Uzbekistan
BOTAGOZ BEGIMBETOVA, Chief Operating officer,
VIVA Pharm LLP
LARISSA YEMELYANOVA, Partner, AEQUITAS law firm
DMITRY KOZENKOV, Head of Pfizer Representative Office in Kazakhstan
ANDREY KONOVALOV, General Director of Teva Kazakhstan"
Hall 2
Effective data management in clinical trials: risks, strategies, and regulatory decisions
- Overview of regulatory requirements in different countries. New regulatory requirements and deadlines for protecting drug registration data.
- What are the main criteria for selecting countries for conducting clinical examinations
- How important is it to conduct clinical trials in countries where drug and medical products are supposed to be regulated
- What additional barriers exist in the organization of clinical trials in different countries, and how can they affect the drug development process?
- Prospects for recognition of CI results
- RWD/RWE – Prospects for the Use of Real-World Clinical Practice Data
- Current Review and Prospects for Adopting the Concept for the Development of Approaches to the Collection, Analysis, and Use of Real-World Clinical Practice Data in the Field of Medicinal Product Circulation in EAEU Member States
- Opportunities for Using RWD/RWE for the Registration of New Medicines and Accelerating the Launch of Innovative and Orphan Drugs, as Well as in the Post-Market Period
- Global Experience in Using Real-World Clinical Practice Data and the Possibility of Implementing Best Practices
SHYNAR BAYDULLAYEVA - Head of the Department of Expertise of Medicines, National Centre for Medicines and Medical Devices Expertise
VADIM KALINICHENKO - Ministry of Health of the Russian Federation, Department of regulation or circulation of medicines and medical devices
ALEXEY KOLBIN, Professor, Head of the Department of Clinical Pharmacology and Evidence-Based Medicine, First Saint Petersburg State Medical University named after Academician I.P. Pavlov, MD (online)
EVGENIA DOLGINA, Director of the Regulatory Department, "Consumer Health" Division, Bayer Russia and CIS
NADEZHDA TIKHONOVA, Senior Director of Clinical Research, AstraZeneca
VADIM KALINICHENKO - Ministry of Health of the Russian Federation, Department of regulation or circulation of medicines and medical devices
ALEXEY KOLBIN, Professor, Head of the Department of Clinical Pharmacology and Evidence-Based Medicine, First Saint Petersburg State Medical University named after Academician I.P. Pavlov, MD (online)
EVGENIA DOLGINA, Director of the Regulatory Department, "Consumer Health" Division, Bayer Russia and CIS
NADEZHDA TIKHONOVA, Senior Director of Clinical Research, AstraZeneca
13:30 – 14:30
13:30 – 14:30
Lunch break
14:30 – 15:30
14:30 – 15:30
Parallel Sessions
Hall 1
COMMERCIAL SEGMENT: Market conditions and prospects. strengthening regulation of the dietary supplements market in the EAEU and Uzbekistan
- What approaches to regulating dietary supplements are used in the EAEU countries and how can they be harmonized?
- How can the risks of counterfeit and low-quality products entering the market be reduced?
- What approaches to the regulation and pricing of dietary supplements are used in the EAEU countries and how can they be harmonized?
- Increasing the transparency of the dietary supplements market through the introduction of a labeling mechanism
- What new technologies and standards will help ensure the safety and effectiveness of dietary supplements?
- How can international practices in the field of dietary supplement regulation be adapted within the Eurasian region?
Moderator:
ALEXANDER ZHESTKOV, Executive Director of the Self-Regulatory Organization "Union of Food Supplement Manufacturers"
LYUBOV ANDREEVA – Project Manager (Dietary Supplements, Medical Devices, and Wheelchairs), Department for Socially Significant Goods, Center for the Development of Advanced Technologies
KARINA BULANOVA – General Director, Zhiznevek
ALEXEY PETRENKO – Director of Global Projects, Eas Strategies
ALEXANDER CHERNICHENKO –CEO, MuseMedia
LILIA DANILOVA, Legal Director for Pfizer in the Middle East and Africa, Saudi Arabia, Turkey, Central Asia and the Caucasus, Russia and Belarus
ALEXANDER ZHESTKOV, Executive Director of the Self-Regulatory Organization "Union of Food Supplement Manufacturers"
LYUBOV ANDREEVA – Project Manager (Dietary Supplements, Medical Devices, and Wheelchairs), Department for Socially Significant Goods, Center for the Development of Advanced Technologies
KARINA BULANOVA – General Director, Zhiznevek
ALEXEY PETRENKO – Director of Global Projects, Eas Strategies
ALEXANDER CHERNICHENKO –CEO, MuseMedia
LILIA DANILOVA, Legal Director for Pfizer in the Middle East and Africa, Saudi Arabia, Turkey, Central Asia and the Caucasus, Russia and Belarus
Hall 2
Investments and development of pharmaceutical clusters and their impact on the growth of the pharmaceutical industry in the countries of the Eurasian region. Distributed manufacturing and infrastructure development.
- Impact of global economic and regional changes on the formation and development of infrastructure.
- What are the benefits and challenges of creating pharmaceutical clusters for local manufacturers?
- Prospects and priorities for localization of drug production. How does the state stimulate investment attraction? What conditions are necessary for the sustainable growth of local production? Does the current strategy of the states of the region contribute to the activation and development of their own RnD developments?
- Readiness and capabilities of local pharmaceutical infrastructure for cooperation with international pharmaceutical companies and technology transfer.
- Mechanisms of State Participation and Support for Local Production: Transformation and New Challenges
NADEZHDA KUZINA, Head of the Investment Projects Department, SK-Pharmacy
IGOR MITROFANOV, General Director, Belfarmprom
ALEXANDER BYKOV, Head of Health Economics Department, R-Pharm (online)
ALEXANDER PANOV – Senior Partner at VERBA LEGAL
TIMUR AMANBEKOV – Director of Government Relations and Communications at Roche Central Asia
ZAFAR VAKHIDOV – Chairman of the Expert Council, Partner at the law firm , Vakhidov Partners
IGOR MITROFANOV, General Director, Belfarmprom
ALEXANDER BYKOV, Head of Health Economics Department, R-Pharm (online)
ALEXANDER PANOV – Senior Partner at VERBA LEGAL
TIMUR AMANBEKOV – Director of Government Relations and Communications at Roche Central Asia
ZAFAR VAKHIDOV – Chairman of the Expert Council, Partner at the law firm , Vakhidov Partners
15:30 – 16:00
15:30 – 16:00
Coffee break and business communication
16:00 – 18:00
16:00 – 18:00
Parallel Sessions
Hall 1
Session of negotiations between pharmaceutical manufacturers and local distributors of the EAEU countries. Signing of a memorandum/resolution/agreement.
1-on-1 meetings with distributors will be held throughout the session in a separate room. Each distributor will be represented by several representatives. A time slot will be allocated for each distributor. The duration of the meeting is 15 minutes. During this time, you will have the opportunity to introduce your company, products or services, find out the need for them from the distributor, ask questions and establish contact for the future. These 1-on-1 meetings offer a unique opportunity to personally meet and talk with representatives of local distributors.
Contact the forum team to receive the list of participants for the negotiation session.
Hall 2
FINAL PANEL: Parallel thematic round tables with regulators and business representatives of the Eurasian region. Final resolution for sustainable and innovative development of the pharmaceutical industry of the EAEU countries.
Presentation of recommendations for each key topic: Leading experts or conference panel moderators summarize the main findings of the discussions and formulate recommendations for country officials.
18:00 – 20:00
18:00 – 20:00
Discussion and signing of a resolution/memorandum/ Summary, awards ceremony, and conclusion of the Forum. Cocktail reception.
Сообщение об успешной отправке!
Contacts
LLP "Adam Smith Eurasia"
Forum Director
Aruzhan Akshabayeva
+7 707 223 30 98
A.Akshabaeva@as-conf.com
For Partnership Opportunities Inquiries
Daulet Orynbasarov
+ 7 777 197 99 08
D.Orynbasarov@as-conf.com
Aruzhan Akshabayeva
+7 707 223 30 98
A.Akshabaeva@as-conf.com
For Partnership Opportunities Inquiries
Daulet Orynbasarov
+ 7 777 197 99 08
D.Orynbasarov@as-conf.com
For Delegate Participation Inquiries
Toleutay Zhantore
+7 771 766 83 93
z.toleutai@as-conf.com
Serikova Svetlana
+7 777 060 92 91
s.serikova@as-conf.com
Toleutay Zhantore
+7 771 766 83 93
z.toleutai@as-conf.com
Serikova Svetlana
+7 777 060 92 91
s.serikova@as-conf.com
Submit Your Question